Advanced Oncotherapy Plc (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, announced today that further to the notification on 22 February 2017, the Company has drawn down the second tranche of £1.3 million (less 5%, in accordance with terms for receipt of 95% of nominal value of each tranche).
Proceeds will continue to be allocated to the Company’s projects and for general working capital purposes. Projects include installation of the LIGHT system at Harley Street; the cost of the redevelopment at Harley Street will be borne by Howard de Walden Estates, as per the original announcement of 28 January 2015.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects. The company continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.
